Pancreatic Cancer Research

ResearcherThe University of Texas MD Anderson Cancer CenterActive in the last 2 years

Jonathan D. Mizrahi

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0002-3710-9742; OpenAlex author ID A5062897162. Sources: OpenAlex.

Their work

Papers
9 (first author 4, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
42
Papers, trials and grants by year

2020: 4 papers · 2021: 2 papers · 2022: none · 2023: none · 2024: none · 2025: 1 paper · 2026: 2 papers

Papers 9

  1. Second-Line Systemic Therapy Following First-Line FOLFIRINOX or NALIRIFOX in Metastatic Pancreatic Ductal Adenocarcinoma: A Systematic Review and Meta-Analysis. Last author DOI 10.1007/s12029-026-01601-z↗
  2. Lymph node-targeted, mKRAS-specific amphiphile vaccine in pancreatic cancer: the randomized phase 2 AMPLIFY-7P trial. Co-author DOI 10.1038/s41591-026-04734-7↗
  3. Novel Therapies for Pancreatic Cancer. First author DOI 10.1200/op.24.00279↗
  4. Antibiotic use influences outcomes in advanced pancreatic adenocarcinoma patients. Co-author DOI 10.1002/cam4.3870↗
  5. Outcomes of patients with metastatic pancreatic cancer who progress on first restaging imaging. First author DOI 10.21037/jgo-20-569↗
  6. Modified gemcitabine plus nab-paclitaxel regimen in advanced pancreatic ductal adenocarcinoma. First author DOI 10.1002/cam4.3229↗
  7. Modified FOLFIRINOX in pancreatic cancer patients Age 75 or older. Co-author DOI 10.1016/j.pan.2020.01.005↗
  8. Pancreatic cancer. Co-author DOI 10.1016/s0140-6736(20)30974-0↗
  9. Dose-modified gemcitabine plus nab-paclitaxel front-line in advanced pancreatic ductal adenocarcinoma with baseline hyperbilirubinemia. First author DOI 10.21037/jgo.2019.10.05↗

Closest collaborators

The 25 strongest of 42 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Shubham Pant · 8 shared papers, 2020–2026 · strength 1.52
  2. Jane Elizabeth Rogers · 6 shared papers, 2020–2026 · strength 0.90
  3. Rachna T. Shroff · 5 shared papers, 2020–2021 · strength 0.61
  4. Milind M. Javle · 5 shared papers, 2020–2021 · strength 0.55
  5. Robert A. Wolff · 5 shared papers, 2020–2021 · strength 0.55
  6. Michael James Overman · 4 shared papers, 2020–2021 · strength 0.43
  7. Gauri Rajani Varadhachary · 4 shared papers, 2020–2021 · strength 0.43
  8. Victoria Chung · 1 shared paper, 2025 · strength 0.42
  9. Passant Shaker · 1 shared paper, 2026 · strength 0.36
  10. Kanwal P. S. Raghav · 3 shared papers, 2020–2021 · strength 0.32
  11. David R. Fogelman · 3 shared papers, 2020–2021 · strength 0.31
  12. Rishi Surana · 2 shared papers, 2020–2021 · strength 0.29
  13. Chirayu Mohindroo · 2 shared papers, 2020–2021 · strength 0.20
  14. Florencia M. McAllister · 2 shared papers, 2020–2021 · strength 0.20
  15. Harshabad Singh · 1 shared paper, 2026 · strength 0.19
  16. Zev A. Wainberg · 1 shared paper, 2026 · strength 0.19
  17. Jennifer Brooke Valerin · 1 shared paper, 2026 · strength 0.19
  18. Naomi H. Fei · 1 shared paper, 2026 · strength 0.19
  19. Alexis Diane Leal · 1 shared paper, 2026 · strength 0.19
  20. Andrew Eugene Hendifar · 1 shared paper, 2026 · strength 0.19
  21. Craig Devoe · 1 shared paper, 2026 · strength 0.19
  22. Syed Mohammad Ali Kazmi · 1 shared paper, 2026 · strength 0.19
  23. Pashtoon Murtaza Kasi · 1 shared paper, 2026 · strength 0.19
  24. Eileen Mary O'Reilly · 1 shared paper, 2026 · strength 0.19
  25. Ben George · 1 shared paper, 2026 · strength 0.19

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.